158 related articles for article (PubMed ID: 36877775)
41. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
[TBL] [Abstract][Full Text] [Related]
42. The Value of Immunohistochemical Methods and Preoperative Magnetic Resonance Imaging Findings in Diagnosis of IDH1 Mutant Glioblastomas.
Kiraz U; Vural C; Turan G; Alparslan B; Dervisoglu E
Turk Neurosurg; 2022; 32(2):228-236. PubMed ID: 34859824
[TBL] [Abstract][Full Text] [Related]
43. Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns.
Lo CM; Weng RC; Cheng SJ; Wang HJ; Hsieh KL
Medicine (Baltimore); 2020 Feb; 99(8):e19123. PubMed ID: 32080088
[TBL] [Abstract][Full Text] [Related]
44. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
[TBL] [Abstract][Full Text] [Related]
45. Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma.
Li ZC; Bai H; Sun Q; Zhao Y; Lv Y; Zhou J; Liang C; Chen Y; Liang D; Zheng H
Cancer Med; 2018 Dec; 7(12):5999-6009. PubMed ID: 30426720
[TBL] [Abstract][Full Text] [Related]
46. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
[TBL] [Abstract][Full Text] [Related]
47. Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Eur Radiol; 2018 Oct; 28(10):4350-4361. PubMed ID: 29721688
[TBL] [Abstract][Full Text] [Related]
48. MRI Atlas of IDH Wild-Type Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes.
Roux A; Roca P; Edjlali M; Sato K; Zanello M; Dezamis E; Gori P; Lion S; Fleury A; Dhermain F; Meder JF; Chrétien F; Lechapt E; Varlet P; Oppenheim C; Pallud J
Radiology; 2019 Dec; 293(3):633-643. PubMed ID: 31592732
[TBL] [Abstract][Full Text] [Related]
49. MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.
Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Hatae R; Yoshimoto K; Mizoguchi M; Suzuki SO; Yoshiura T; Honda H
AJNR Am J Neuroradiol; 2016 Jan; 37(1):58-65. PubMed ID: 26405082
[TBL] [Abstract][Full Text] [Related]
50. Gyriform infiltration as imaging biomarker for molecular glioblastomas.
Mesny E; Barritault M; Izquierdo C; Poncet D; d'Hombres A; Guyotat J; Jouanneau E; Ameli R; Honnorat J; Meyronet D; Ducray F
J Neurooncol; 2022 May; 157(3):511-521. PubMed ID: 35364762
[TBL] [Abstract][Full Text] [Related]
51. T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma.
Auer TA; Kern M; Fehrenbach U; Tanyldizi Y; Misch M; Wiener E
Neuroradiol J; 2021 Oct; 34(5):392-400. PubMed ID: 33573473
[TBL] [Abstract][Full Text] [Related]
52. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
[TBL] [Abstract][Full Text] [Related]
53. Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy.
Natsumeda M; Motohashi K; Igarashi H; Nozawa T; Abe H; Tsukamoto Y; Ogura R; Okada M; Kobayashi T; Aoki H; Takahashi H; Kakita A; Okamoto K; Nakada T; Fujii Y
Neurosurg Rev; 2018 Apr; 41(2):641-647. PubMed ID: 28956184
[TBL] [Abstract][Full Text] [Related]
54. Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.
Wu H; Tong H; Du X; Guo H; Ma Q; Zhang Y; Zhou X; Liu H; Wang S; Fang J; Zhang W
Eur Radiol; 2020 Jun; 30(6):3254-3265. PubMed ID: 32078014
[TBL] [Abstract][Full Text] [Related]
55.
Senhaji N; Louati S; Chbani L; El Fatemi H; Hammas N; Mikou K; Maaroufi M; Benzagmout M; Boujraf S; El Bardai S; Giry M; Marie Y; Chaoui El Faiz M; Mokhtari K; Idbaih A; Amarti A; Bennis S
Biomed Res Int; 2017; 2017():8045859. PubMed ID: 28785587
[TBL] [Abstract][Full Text] [Related]
56. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
[TBL] [Abstract][Full Text] [Related]
57. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
58. Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
Yamashita K; Hatae R; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Yamashita Y; Kuga D; Hata N; Yoshimoto K; Suzuki SO; Iwaki T; Iihara K; Honda H
Diagn Interv Imaging; 2019; 100(7-8):411-419. PubMed ID: 30948344
[TBL] [Abstract][Full Text] [Related]
59. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
[TBL] [Abstract][Full Text] [Related]
60. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]